Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

AMP.K-4

59 views

Published on

  • Be the first to comment

  • Be the first to like this

AMP.K-4

  1. 1. Concept Innovate presents: ResveraTech Chiao Chang Prateek Diwan Lucas C Rodriguez
  2. 2. Chronic Pain Man On Fire: • 25% of Americans suffer from chronic pain • Nearly 50% do not get effective relief from current therapies • Post surgical pain often clear culprits • In many common conditions such as diabetic neuropathy, no clear source of pain is found. • The annual cost of chronic pain is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.
  3. 3. Innovation of tomorrows pain relief solutions ResveraTech Amare Stoudemire… Why are you in a tub of wine???
  4. 4. • All natural (homeopathic) • Found in wine, and dark chocolate • Potential usage: • Heart Disease • Cancer • Metabolism • Lifespan • Pain relief Resveratrol
  5. 5. Types of pain… How is it currently treated??? What can be done??? Types of Pain
  6. 6. Acute Versus Chronic Types of Pain
  7. 7. Biochemistry of Pain Pain Activator Pain Activator Middle -Men Middle -Men Complex Ribo
  8. 8. Efficacy
  9. 9. • OTC market as of 2013 ~ $6Billion • Internal Analgesic ~ 60% • External Analgesic ~ 15% • GIA estimates $34.6Billion in analgesic market by 2015. Market
  10. 10. Platform Technology ResveraDerm Creme Pain Relief Patch Post-Surgical Pain Relief Bandage Pain Relief Sutures
  11. 11. ResveraDerm Clinical Feasibility Study Customer Acquisition and Backing • Physical Therapists • Elderly post-surgery patients • Orthopedics • Sports injury • Chiropractors • Homeopathic • Medical spas and Compounding Pharmacists • Massage • Homeopathic • Western Medicine • Pain Relief Centers • Desperate for pain relief Marketing Plan
  12. 12. • Finish development of platform • CMO manufacture agreement • Data acquisition for downstream (IP protection) • Website Design • Clinical feasibility • Large retail Sales • Website • Clinic / Retail • Distributer Strategy
  13. 13. Strategy ResveraTech
  14. 14. • BASF is an international chemical manufacturer • Agreement in place: ResveraDerm development R&D Manufacturer • Manufacture product for : • Fee for service • Royalty • Save startup capital Contract Manufacture
  15. 15. Timeline 2011 2012 2013 2014 2015 2016 2017 2018 Hard Launch Patch, Bandage, Sutures Phase III Begin (Commercialization, Angel/VC Funding) Phase II Complete (Patch, Bandage, and Sutures Ready for Launch) Break Even Phase II Approval (Development of Downstream Products) Hard Launch ResveraDerm (Large Retail) Downstream Product IP Acquired Phase I End Soft Launch ResveraDerm (Clinical Feasibility Study) SBIR/STTR Phase I Approval Submission of SBIR/STTR Draft of SBIR/STTR Business Planning Begin Publication III Publication II Publication I • Phase I: • Feasibility • Clinical Study • 6 months : $150k • Hard Launch ResveraDerm • Phase II: • Downstream Product Development • 2 years : $750k • Phase III (Commercialization) • Angel/VC: • Strong track via SBIR • Manufacturer contract • Ready for sales
  16. 16. $0 $500,000 $1,000,000 $1,500,000 $2,000,000 $2,500,000 $3,000,000 $3,500,000 8000 58,000 118,000 178,250 239,750 301,750 364,750 Units Sold Revenue vs. Unit Sales Sales Total Costs Fixed Costs: $626,820 Variable Cost per Unit: $3 Unit Price: $7.20 Unit Increments: 10,000 BREAK-EVEN POINT: 149,243 Projections
  17. 17. • Fixed and variable costs analyzed • Conservative Assumptions • low price point • two marketing channels • Concentrate efforts on TX, NM, AR, LA • Market penetration based on Lidoderm 1999 • Manufacturing keeps up with sales $0.10 $2.00 $5.00 $10.00 $50.00 $100.00 $0.0 $10.0 $20.0 $30.0 $40.0 $50.0 $60.0 $70.0 $80.0 $90.0 $100.0 2014 2015 2016 2017 2018 2019 2020 Sales in Millions Revenue Projections
  18. 18. Financials TOP DOWN Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 Market $500,000,000.00 $500,000,000.00 $500,000,000.00 $500,000,000.00 $500,000,000.00 $500,000,000.00 Penetration 0 0.1% 0.2% 0.4% 0.8% 1.6% Rev $- $500,000.00 $1,000,000.00 $2,000,000.00 $4,000,000.00 $8,000,000.00 Costs $- $650,000.00 $767,000.00 $905,060.00 $1,067,970.80 $1,260,205.54 Profit $- $(150,000.00) $233,000.00 $1,094,940.00 $2,932,029.20 $6,739,794.46 BOTTOM UP Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 Units 0 50000.00 87500.00 153125.00 267968.75 468945.31 Locations (at 2:1 C:R) 0 125.00 218.75 382.81 669.92 1172.36 Sales Rev 0 500000.00 875000.00 1531250.00 2679687.50 4689453.13 Costs $ - $650,000.00 $767,000.00 $905,060.00 $1,067,970.80 $1,260,205.54 Profit $ - $(150,000.00) $108,000.00 $626,190.00 $1,611,716.70 $3,429,247.58
  19. 19. Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 $(150,000) $(500,000.00) $500,000.00 $1,500,000.00 $2,500,000.00 $3,500,000.00 $4,500,000.00 $5,500,000.00 $6,500,000.00 $7,500,000.00 Financials (150,000) $(500,000.00) $500,000.00 $1,500,000.00 $2,500,000.00 $3,500,000.00 $4,500,000.00 $5,500,000.00 $6,500,000.00 $7,500,000.00 Sales in Millions
  20. 20. Concept Innovate • Well-Educated • R&D Experience • Marketing • Sales • Motivated • Adaptable • Strong Strategy • Mentor Backing
  21. 21. Team Madison PedigoJackie Kimzey Greg Dussor Ted Price Inventors Mentors
  22. 22. • All-natural, homeopathic substance • Low cost • Available • No side effects • Proven Effectiveness • Multiple Usages (Platform Technology) In Summary…

×